Treatment outcomes of acute bipolar depressive episode with psychosis

Marco Antonio Caldieraro, Steven Dufour, Louisa G. Sylvia, Keming Gao, Terence A. Ketter, William V Bobo, Samantha Walsh, Jessica Janos, Mauricio Tohen, Noreen A. Reilly-Harrington, Susan L. McElroy, Richard C. Shelton, Charles L. Bowden, Thilo Deckersbach, Andrew A. Nierenberg

Research output: Contribution to journalArticle

Abstract

Background: The impact of psychosis on the treatment of bipolar depression is remarkably understudied. The primary aim of this study was to compare treatment outcomes of bipolar depressed individuals with and without psychosis. The secondary aim was to compare the effect of lithium and quetiapine, each with adjunctive personalized treatments (APTs), in the psychotic subgroup. Methods: We assessed participants with DSM-IV bipolar depression included in a comparative effectiveness study of lithium and quetiapine with APTs (the Bipolar CHOICE study). Severity was assessed by the Bipolar Inventory of Symptoms Scale (BISS) and by the Clinical Global Impression Scale–Severity–Bipolar Version (CGI-S-BP). Mixed models were used to assess the course of symptom change, and Cox regression survival analysis was used to assess the time to remission. Results: Psychotic features were present in 10.6% (n = 32) of the depressed participants (n = 303). Those with psychotic features had higher scores on the BISS before (75.2 ± 17.6 vs. 54.9 ± 16.3; P <.001) and after (37.2 ± 19.7 vs. 26.3 ± 18.0; P =.003) 6-month treatment. The CGI-S-BP yielded similar results. Participants with and without psychosis had similar course of symptom improvement and similar time to remission. There was no significant difference in the treatment outcomes of lithium (n = 11) and quetiapine (n = 21) among the psychotic subgroup. Conclusion: Bipolar depressive episodes with psychotic features are more severe, and compared to nonpsychotic depressions, present a similar course of improvement. Given the small number of participants presenting psychosis, the lack of statistically significant difference between lithium- and quetiapine-based treatment of psychotic bipolar depressive episodes needs replication in a larger sample.

Original languageEnglish (US)
Pages (from-to)402-410
Number of pages9
JournalDepression and Anxiety
Volume35
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Lithium
Psychotic Disorders
Bipolar Disorder
Equipment and Supplies
Survival Analysis
Diagnostic and Statistical Manual of Mental Disorders
Regression Analysis
Depression
Quetiapine Fumarate

Keywords

  • bipolar depression
  • bipolar disorder
  • psychosis
  • psychotic mood disorders
  • treatment outcome

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Caldieraro, M. A., Dufour, S., Sylvia, L. G., Gao, K., Ketter, T. A., Bobo, W. V., ... Nierenberg, A. A. (2018). Treatment outcomes of acute bipolar depressive episode with psychosis. Depression and Anxiety, 35(5), 402-410. https://doi.org/10.1002/da.22716

Treatment outcomes of acute bipolar depressive episode with psychosis. / Caldieraro, Marco Antonio; Dufour, Steven; Sylvia, Louisa G.; Gao, Keming; Ketter, Terence A.; Bobo, William V; Walsh, Samantha; Janos, Jessica; Tohen, Mauricio; Reilly-Harrington, Noreen A.; McElroy, Susan L.; Shelton, Richard C.; Bowden, Charles L.; Deckersbach, Thilo; Nierenberg, Andrew A.

In: Depression and Anxiety, Vol. 35, No. 5, 01.05.2018, p. 402-410.

Research output: Contribution to journalArticle

Caldieraro, MA, Dufour, S, Sylvia, LG, Gao, K, Ketter, TA, Bobo, WV, Walsh, S, Janos, J, Tohen, M, Reilly-Harrington, NA, McElroy, SL, Shelton, RC, Bowden, CL, Deckersbach, T & Nierenberg, AA 2018, 'Treatment outcomes of acute bipolar depressive episode with psychosis', Depression and Anxiety, vol. 35, no. 5, pp. 402-410. https://doi.org/10.1002/da.22716
Caldieraro MA, Dufour S, Sylvia LG, Gao K, Ketter TA, Bobo WV et al. Treatment outcomes of acute bipolar depressive episode with psychosis. Depression and Anxiety. 2018 May 1;35(5):402-410. https://doi.org/10.1002/da.22716
Caldieraro, Marco Antonio ; Dufour, Steven ; Sylvia, Louisa G. ; Gao, Keming ; Ketter, Terence A. ; Bobo, William V ; Walsh, Samantha ; Janos, Jessica ; Tohen, Mauricio ; Reilly-Harrington, Noreen A. ; McElroy, Susan L. ; Shelton, Richard C. ; Bowden, Charles L. ; Deckersbach, Thilo ; Nierenberg, Andrew A. / Treatment outcomes of acute bipolar depressive episode with psychosis. In: Depression and Anxiety. 2018 ; Vol. 35, No. 5. pp. 402-410.
@article{04e1befd81ae4e9ebb933232c997ca3e,
title = "Treatment outcomes of acute bipolar depressive episode with psychosis",
abstract = "Background: The impact of psychosis on the treatment of bipolar depression is remarkably understudied. The primary aim of this study was to compare treatment outcomes of bipolar depressed individuals with and without psychosis. The secondary aim was to compare the effect of lithium and quetiapine, each with adjunctive personalized treatments (APTs), in the psychotic subgroup. Methods: We assessed participants with DSM-IV bipolar depression included in a comparative effectiveness study of lithium and quetiapine with APTs (the Bipolar CHOICE study). Severity was assessed by the Bipolar Inventory of Symptoms Scale (BISS) and by the Clinical Global Impression Scale–Severity–Bipolar Version (CGI-S-BP). Mixed models were used to assess the course of symptom change, and Cox regression survival analysis was used to assess the time to remission. Results: Psychotic features were present in 10.6{\%} (n = 32) of the depressed participants (n = 303). Those with psychotic features had higher scores on the BISS before (75.2 ± 17.6 vs. 54.9 ± 16.3; P <.001) and after (37.2 ± 19.7 vs. 26.3 ± 18.0; P =.003) 6-month treatment. The CGI-S-BP yielded similar results. Participants with and without psychosis had similar course of symptom improvement and similar time to remission. There was no significant difference in the treatment outcomes of lithium (n = 11) and quetiapine (n = 21) among the psychotic subgroup. Conclusion: Bipolar depressive episodes with psychotic features are more severe, and compared to nonpsychotic depressions, present a similar course of improvement. Given the small number of participants presenting psychosis, the lack of statistically significant difference between lithium- and quetiapine-based treatment of psychotic bipolar depressive episodes needs replication in a larger sample.",
keywords = "bipolar depression, bipolar disorder, psychosis, psychotic mood disorders, treatment outcome",
author = "Caldieraro, {Marco Antonio} and Steven Dufour and Sylvia, {Louisa G.} and Keming Gao and Ketter, {Terence A.} and Bobo, {William V} and Samantha Walsh and Jessica Janos and Mauricio Tohen and Reilly-Harrington, {Noreen A.} and McElroy, {Susan L.} and Shelton, {Richard C.} and Bowden, {Charles L.} and Thilo Deckersbach and Nierenberg, {Andrew A.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1002/da.22716",
language = "English (US)",
volume = "35",
pages = "402--410",
journal = "Depression and Anxiety",
issn = "1091-4269",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Treatment outcomes of acute bipolar depressive episode with psychosis

AU - Caldieraro, Marco Antonio

AU - Dufour, Steven

AU - Sylvia, Louisa G.

AU - Gao, Keming

AU - Ketter, Terence A.

AU - Bobo, William V

AU - Walsh, Samantha

AU - Janos, Jessica

AU - Tohen, Mauricio

AU - Reilly-Harrington, Noreen A.

AU - McElroy, Susan L.

AU - Shelton, Richard C.

AU - Bowden, Charles L.

AU - Deckersbach, Thilo

AU - Nierenberg, Andrew A.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: The impact of psychosis on the treatment of bipolar depression is remarkably understudied. The primary aim of this study was to compare treatment outcomes of bipolar depressed individuals with and without psychosis. The secondary aim was to compare the effect of lithium and quetiapine, each with adjunctive personalized treatments (APTs), in the psychotic subgroup. Methods: We assessed participants with DSM-IV bipolar depression included in a comparative effectiveness study of lithium and quetiapine with APTs (the Bipolar CHOICE study). Severity was assessed by the Bipolar Inventory of Symptoms Scale (BISS) and by the Clinical Global Impression Scale–Severity–Bipolar Version (CGI-S-BP). Mixed models were used to assess the course of symptom change, and Cox regression survival analysis was used to assess the time to remission. Results: Psychotic features were present in 10.6% (n = 32) of the depressed participants (n = 303). Those with psychotic features had higher scores on the BISS before (75.2 ± 17.6 vs. 54.9 ± 16.3; P <.001) and after (37.2 ± 19.7 vs. 26.3 ± 18.0; P =.003) 6-month treatment. The CGI-S-BP yielded similar results. Participants with and without psychosis had similar course of symptom improvement and similar time to remission. There was no significant difference in the treatment outcomes of lithium (n = 11) and quetiapine (n = 21) among the psychotic subgroup. Conclusion: Bipolar depressive episodes with psychotic features are more severe, and compared to nonpsychotic depressions, present a similar course of improvement. Given the small number of participants presenting psychosis, the lack of statistically significant difference between lithium- and quetiapine-based treatment of psychotic bipolar depressive episodes needs replication in a larger sample.

AB - Background: The impact of psychosis on the treatment of bipolar depression is remarkably understudied. The primary aim of this study was to compare treatment outcomes of bipolar depressed individuals with and without psychosis. The secondary aim was to compare the effect of lithium and quetiapine, each with adjunctive personalized treatments (APTs), in the psychotic subgroup. Methods: We assessed participants with DSM-IV bipolar depression included in a comparative effectiveness study of lithium and quetiapine with APTs (the Bipolar CHOICE study). Severity was assessed by the Bipolar Inventory of Symptoms Scale (BISS) and by the Clinical Global Impression Scale–Severity–Bipolar Version (CGI-S-BP). Mixed models were used to assess the course of symptom change, and Cox regression survival analysis was used to assess the time to remission. Results: Psychotic features were present in 10.6% (n = 32) of the depressed participants (n = 303). Those with psychotic features had higher scores on the BISS before (75.2 ± 17.6 vs. 54.9 ± 16.3; P <.001) and after (37.2 ± 19.7 vs. 26.3 ± 18.0; P =.003) 6-month treatment. The CGI-S-BP yielded similar results. Participants with and without psychosis had similar course of symptom improvement and similar time to remission. There was no significant difference in the treatment outcomes of lithium (n = 11) and quetiapine (n = 21) among the psychotic subgroup. Conclusion: Bipolar depressive episodes with psychotic features are more severe, and compared to nonpsychotic depressions, present a similar course of improvement. Given the small number of participants presenting psychosis, the lack of statistically significant difference between lithium- and quetiapine-based treatment of psychotic bipolar depressive episodes needs replication in a larger sample.

KW - bipolar depression

KW - bipolar disorder

KW - psychosis

KW - psychotic mood disorders

KW - treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85046337565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046337565&partnerID=8YFLogxK

U2 - 10.1002/da.22716

DO - 10.1002/da.22716

M3 - Article

C2 - 29329498

AN - SCOPUS:85046337565

VL - 35

SP - 402

EP - 410

JO - Depression and Anxiety

JF - Depression and Anxiety

SN - 1091-4269

IS - 5

ER -